Capital Counsel LLC NY Has $7.67 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Capital Counsel LLC NY lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,210 shares of the biopharmaceutical company’s stock after purchasing an additional 1,058 shares during the period. Gilead Sciences accounts for about 0.3% of Capital Counsel LLC NY’s portfolio, making the stock its 17th biggest position. Capital Counsel LLC NY’s holdings in Gilead Sciences were worth $7,673,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in GILD. Brighton Jones LLC lifted its position in shares of Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after acquiring an additional 2,450 shares during the period. Bison Wealth LLC bought a new stake in Gilead Sciences in the fourth quarter valued at $215,000. XTX Topco Ltd raised its holdings in shares of Gilead Sciences by 76.8% during the first quarter. XTX Topco Ltd now owns 9,156 shares of the biopharmaceutical company’s stock valued at $1,026,000 after purchasing an additional 3,976 shares during the period. Baker Avenue Asset Management LP acquired a new position in shares of Gilead Sciences during the first quarter valued at about $279,000. Finally, PNC Financial Services Group Inc. boosted its position in shares of Gilead Sciences by 3.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 408,113 shares of the biopharmaceutical company’s stock worth $45,729,000 after purchasing an additional 14,312 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the completion of the sale, the chief executive officer directly owned 581,203 shares of the company’s stock, valued at approximately $69,389,826.17. This trade represents a 1.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Monday, November 17th. The stock was sold at an average price of $125.23, for a total value of $313,075.00. Following the sale, the chief financial officer owned 154,555 shares in the company, valued at $19,354,922.65. This trade represents a 1.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 115,146 shares of company stock worth $14,012,141. Corporate insiders own 0.27% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on GILD. UBS Group boosted their target price on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research report on Friday, August 8th. Wells Fargo & Company upped their target price on Gilead Sciences from $140.00 to $145.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Mizuho upped their target price on Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a research report on Friday, November 21st. Cantor Fitzgerald reissued an “overweight” rating and issued a $135.00 price target on shares of Gilead Sciences in a research report on Friday, October 31st. Finally, TD Cowen boosted their price target on shares of Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $130.65.

Gilead Sciences Stock Down 1.3%

Shares of NASDAQ:GILD opened at $125.85 on Monday. The stock has a market cap of $156.13 billion, a price-to-earnings ratio of 25.07, a PEG ratio of 0.81 and a beta of 0.32. The business’s 50 day moving average is $119.87 and its 200 day moving average is $114.70. Gilead Sciences, Inc. has a 12-month low of $88.57 and a 12-month high of $128.70. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s dividend payout ratio is presently 48.99%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.